• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Korro Bio Inc.

    2/14/25 7:52:16 AM ET
    $KRRO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRRO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Korro Bio, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    500946108

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    500946108


    1Names of Reporting Persons

    DRIEHAUS CAPITAL MANAGEMENT LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    494,905.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    494,905.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    494,905.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.28 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Korro Bio, Inc.
    (b)Address of issuer's principal executive offices:

    60 First Street, 2nd Floor, Suite 250, Cambridge, Massachusetts, 02141
    Item 2. 
    (a)Name of person filing:

    Driehaus Capital Management LLC
    (b)Address or principal business office or, if none, residence:

    25 East Erie Street, Chicago, Illinois 60611
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    500946108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    494905
    (b)Percent of class:

    5.28  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    494905

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    494905

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM. Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power. To the best of DCM's knowledge, none of the referenced clients have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DRIEHAUS CAPITAL MANAGEMENT LLC
     
    Signature:Janet McWilliams
    Name/Title:Janet McWilliams, General Counsel
    Date:02/14/2025
    Get the next $KRRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRRO

    DatePrice TargetRatingAnalyst
    4/29/2025$74.00Overweight
    Cantor Fitzgerald
    4/16/2025$25.00Buy
    Chardan Capital Markets
    1/10/2025$155.00Outperform
    Oppenheimer
    10/21/2024$153.00Strong Buy
    Raymond James
    8/14/2024$180.00Outperform
    William Blair
    3/28/2024$100.00 → $115.00Buy
    H.C. Wainwright
    2/27/2024$120.00Outperform
    BMO Capital Markets
    12/4/2023$100.00Buy
    H.C. Wainwright
    More analyst ratings

    $KRRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mathers Edward T bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Florence Anthony A. Jr. bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:26 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Yang Rick bought $999,992 worth of shares (17,857 units at $56.00) (SEC Form 4)

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/24/24 5:00:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Korro Bio Inc.

      10-Q - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:40:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - Korro Bio, Inc. (0001703647) (Filer)

      5/7/25 4:35:10 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Korro Bio Inc.

      DEFA14A - Korro Bio, Inc. (0001703647) (Filer)

      4/29/25 6:06:51 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Korro Bio with a new price target

      Cantor Fitzgerald initiated coverage of Korro Bio with a rating of Overweight and set a new price target of $74.00

      4/29/25 8:10:45 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Korro Bio with a new price target

      Chardan Capital Markets initiated coverage of Korro Bio with a rating of Buy and set a new price target of $25.00

      4/16/25 9:07:30 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Korro Bio with a new price target

      Oppenheimer initiated coverage of Korro Bio with a rating of Outperform and set a new price target of $155.00

      1/10/25 8:59:40 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Korro to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Jefferies Global Healthcare Conference Dr. Aiyar and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will present on Wednesday, June 4, 2025, at 9:55 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference Dr. Aiyar and Dr. Olugemo, will present on Monday, June 9, 2025, at 4:00 p.m. ET. A live webc

      5/14/25 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

      —Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025  —Streamlining operations and focusing on delivering potential value generating program milestones, with workforce reduction of approximately 20% and cost reductions expected to extend cash runway into 2027   —Second development candidate expected to be announced in 2025  —Ended first quarter 2025 with $139.0 million in cash, cash equivalents and marketable securities     CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of gene

      5/7/25 4:30:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Vincent Loic A

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:46:16 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Senior Vice President, Finance Dolan Oliver

      4 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:46:19 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Vincent Loic A

      3 - Korro Bio, Inc. (0001703647) (Issuer)

      4/1/25 9:43:14 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 7:54:42 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 3:04:22 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Korro Bio Inc.

      SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

      11/14/24 12:21:08 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

      4/1/25 7:30:00 AM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

      - Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

      11/12/24 4:05:00 PM ET
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care